December 18, 2015
An Illinois federal judge stopped a patent infringement suit against Allergan Inc. on Friday pending the U.S. Patent and Trademark Office's review of a Canadian company's patent covering pain treatment with the active ingredient in Botox, which Allergan says is invalid and unenforceable.